GlassScriptPhysician profile
Sarah A Digby
NPI 1417024704
$7,193.04
in general payments reported to CMS, 2019-2025
40 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $1,646 · 2021: $1,455 · 2022: $876 · 2023: $872 · 2024: $794 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,480.23 | 2019-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $972.25 | 2019-2024 | Jardiance |
| Abbvie INC. | $825.49 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $635.71 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $462.89 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $300.49 | 2020-2023 | Zepbound |
| Sanofi-Aventis U.S. LLC | $273.74 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $238.87 | 2020-2021 | |
| Amarin Pharma, INC. | $206.67 | 2019-2021 | |
| Abbott Laboratories | $191.67 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $190.89 | 2019-2021 | |
| Amgen INC. | $139.59 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $126.60 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $104.21 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.09 | 2020-2024 | Xifaxan |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Digby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.